Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect
Erica Salvati, Carlo Leonetti, Angela Rizzo, Marco Scarsella, Marcella Mottolese, Rossella Galati, Isabella Sperduti, Malcolm F.G. Stevens, Maurizio D’Incalci, Maria Blasco, Giovanna Chiorino, Serge Bauwens, Béatrice Horard, Eric Gilson, Antonella Stoppacciaro, Gabriella Zupi, Annamaria Biroccio
Erica Salvati, Carlo Leonetti, Angela Rizzo, Marco Scarsella, Marcella Mottolese, Rossella Galati, Isabella Sperduti, Malcolm F.G. Stevens, Maurizio D’Incalci, Maria Blasco, Giovanna Chiorino, Serge Bauwens, Béatrice Horard, Eric Gilson, Antonella Stoppacciaro, Gabriella Zupi, Annamaria Biroccio
View: Text | PDF
Research Article

Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect

  • Text
  • PDF
Abstract

Functional telomeres are required for the replicability of cancer cells. The G-rich strand of telomeric DNA can fold into a 4-stranded structure known as the G-quadruplex (G4), whose stabilization alters telomere function limiting cancer cell growth. Therefore, the G4 ligand RHPS4 may possess antitumor activity. Here, we show that RHPS4 triggers a rapid and potent DNA damage response at telomeres in human transformed fibroblasts and melanoma cells, characterized by the formation of several telomeric foci containing phosphorylated DNA damage response factors γ-H2AX, RAD17, and 53BP1. This was dependent on DNA repair enzyme ATR, correlated with delocalization of the protective telomeric DNA–binding protein POT1, and was antagonized by overexpression of POT1 or TRF2. In mice, RHPS4 exerted its antitumor effect on xenografts of human tumor cells of different histotype by telomere injury and tumor cell apoptosis. Tumor inhibition was accompanied by a strong DNA damage response, and tumors overexpressing POT1 or TRF2 were resistant to RHPS4 treatment. These data provide evidence that RHPS4 is a telomere damage inducer and that telomere disruption selectively triggered in malignant cells results in a high therapeutic index in mice. They also define a functional link between telomere damage and antitumor activity and reveal the key role of telomere-protective factors TRF2 and POT1 in response to this anti-telomere strategy.

Authors

Erica Salvati, Carlo Leonetti, Angela Rizzo, Marco Scarsella, Marcella Mottolese, Rossella Galati, Isabella Sperduti, Malcolm F.G. Stevens, Maurizio D’Incalci, Maria Blasco, Giovanna Chiorino, Serge Bauwens, Béatrice Horard, Eric Gilson, Antonella Stoppacciaro, Gabriella Zupi, Annamaria Biroccio

×

Figure 7

TRF2- or POT1-overexpressing tumors were resistant to RHPS4, as TRF2 and POT1 antagonized telomere dysfunction–mediated effects of this ligand.

Options: View larger image (or click on image) Download as PowerPoint
TRF2- or POT1-overexpressing tumors were resistant to RHPS4, as TRF2 and...
Mice were implanted intramuscularly with M14 melanoma cells overexpressing TRF1, TRF2, POT1, or puromycin-resistant gene only (Empty). (A) Antitumor activity of RHPS4 in tumors overexpressing TRF1, TRF2, POT1, or the empty vector. Mean tumor weights in untreated (filled squares) and RHPS4-treated (open squares) mice. Points represent mean (bars, SD). Arrow indicates the start of treatment. (B–G) Immunohistochemical analysis of TRF2, POT1, and TRF1 in sections of empty vector– (B, C, and D), TRF2- (E), POT1- (F), and TRF1-transfected (G) tumors excised on day 25 after tumor implantation. TRF2 expression was revealed using anti-TRF2 mAb (B and E), while POT1 (C and F) and TRF1 (D and G) were detected by anti-Flag mAb. Original magnification, ×40. (H) Apoptotic index (AI; gray bars) and PI (white bars; mean percentage) in the indicated groups untreated (–) and treated with RHPS4 (+) as indicated by TUNEL and Ki-67 staining. The analysis was performed at the end of treatment and was repeated 3 times using 3 different tumors for each point. The mean of 3 independent experiments is reported (SD was less than 10%). (I) Immunohistochemical analysis of γ-H2AX in tumor sections from the indicated groups. Original magnification, ×40. (J) Atypical mitotic index (AMI) in tumor sections from the indicated groups untreated (white bars) and treated with RHPS4 (gray bars).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts